Value of the tumor marker CA 19-9 in the differential diagnosis of lesions of the head of the pancreas;Stellenwert des tumormarkers CA 19-9 in der differentialdiagnose von raumforderungen im pankreaskopf

Chirurg

Volumn 67, Issue 10, 1996, Pages 1007-1011

  Bottger Th ^a   Hassdenteufel A ^a   Boddin, J ^a   Kuchle R ^a   Junginger, Th ^a   Prellwitz, W ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

CA 19 9; Pancreatic cancer

Indexed keywords

ALKALINE PHOSPHATASE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT TUMOR; BLOOD; CANCER STAGING; CHRONIC DISEASE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PAGET NIPPLE DISEASE; PANCREAS; PANCREAS TUMOR; PANCREATITIS; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; VATER PAPILLA;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; AMPULLA OF VATER; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, DUCTAL, BREAST; CHRONIC DISEASE; COMMON BILE DUCT NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0030256198     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00002512     Document Type: Article

References (19)

1. Banfi G, Zerbi A, Pastori S, Parolini D, et al (1993) Behavior of tumor markers CA 19.9, CA 195, CAM 43, CA 242 and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 39: 420
2. Beretta E, Malesci A, Zerbi A, Mariani A, et al (1987) Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 60: 2428
3. Frebourg Th, Bercoff E, Manchon N, Senant J, et al (1988) The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. Cancer 62: 2287
4. Glenn J, Steinberg WM, Kurtzmann SH, Stienberg SM, Sindelar WF (1988) Evaluation of the utility of a radioimmunoassay for scrum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 6: 462
5. Gupta MK, Arciaga R, Bocci L, Tubbs R, et al (1985) Measurement of a monoclonal-antibody-defined antigen (CA 19-9) in the sera of patients with malignant and nonmalignant diseases. Cancer 56: 277
6. Haglund C, Roberst PJ, Kuusela P, Scheinin TM, et al (1986) Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 53: 197
7. Heptner G, Domschke S, Schneider MU, Domschke W (1985) Bedeutung des tumorassoziierten Antigens CA 19-9 in der Differentialdiagnose von Pankreaserkrankungen. Dtsch Med Wochenschr 110: 624
8. Klapdor R, Klapdor U, Bahlo M, Dallek M, et al (1984) CA 12-5 bei Karzinomen des Verdauungstraktes. Dtsch Med Wochenschr 109: 1949
9. Lowenfels AB, Maisonneuve P, Cavallini G (1993) Pancreatitis and the risk of pancreatic cancer. N Engl J Med 328: 1433
10. Lundin J, Roberts PJ, Kuusela P, Haglund C (1994) The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 69: 515
11. Malesci A, Montorsi M, Mariani A, Santambrogio R, et al (1992) Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study. Pancreas 7: 497
12. Safi F, Roscher R, Beger HG (1989) Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9. Hepatogastroenterology 36: 419
13. Satake K, Chung YS, Yokomatsu H, Nakata B, et al (1991) Various tumour markers for small pancreatic cancer with special reference to the present status of pancreatic cancer in Japan and our experience over the past 2 years. Pancreas 6: 234
14. Sperti C, Pasquali C, Catalini S, Cappellazzo F, et al (1993) CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 52: 138
15. Steinberg WM, Gelfand R, Anderson KK, Glenn J, et al (1986) Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of pancreas. Gastroenterology 90: 343
16. Steinberg WM (1990) The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 85: 350
17. Tian F, Appert HE, Myles J, Howard JM (1992) Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 215: 350
18. Von Rosen A, Linder S, Harmenberg U, Wiechel K (1992) Clinical relevance of tumour markers CA 19-9 and CA-50 in sera from patients with pancreatic duct carcinoma. Surg Oncol 1: 109
19. Von Rosen A, Linder S, Harmenberg U, Pegert S (1993) Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas 8: 160